RT Journal Article
SR Electronic
T1 Radiation Therapy for Anal Squamous Cell Carcinoma: A Retrospective Multicenter Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6931
OP 6938
DO 10.21873/anticanres.13071
VO 38
IS 12
A1 HYEON KANG KOH
A1 KYUBO KIM
A1 WON IL JANG
A1 CHANG HOON SONG
A1 AH RAM CHANG
A1 HAE JIN PARK
A1 KYUNG SU KIM
A1 JI HYUN CHANG
A1 MI-SOOK KIM
YR 2018
UL http://ar.iiarjournals.org/content/38/12/6931.abstract
AB Aim: To analyze the treatment outcomes, patterns of failures and prognostic factors for patients with anal cancer treated with radiotherapy (RT). Materials and Methods: Between January 2000 and December 2015, 83 patients with anal squamous cell carcinoma were treated with definitive RT. The median RT dose applied to the primary carcinoma site was 55 (range=45-64) Gy. Seventy-six patients (91.6%) received concurrent chemotherapy, and the most common regimen was 5-fluorouracil plus mitomycin C. Results: The median age of patients was 64 (range=36-86) years, and there were 21 males and 62 females. The overall complete remission rate was 89.2%. The median duration of follow-up was 51 (range=3-173) months. The actuarial 5-year overall, progression-free survival (PFS), locoregional progression-free, and distant metastasis-free survival rates were 85.0%, 70.4%, 78.2%, and 82.6%, respectively. On multivariate analysis, eventual treatment response was the only prognostic factor for overall (p=0.023) and progression-free (p<0.001) survival. Age (p=0.013) and eventual treatment response (p<0.001) were significantly associated with locoregional progression-free survival. Initial treatment response, lymph node involvement and RT technique significantly affected distant metastasis-free survival (p=0.016, 0.048 and 0.002, respectively). Conclusion: RT, mainly with concurrent chemotherapy, showed acceptable treatment outcomes and safe toxicity profiles.